Advanced searches left 3/3

Carbon-13 - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 November 2022

* If you want to update the article please login/register

A Phase I/II Study of Hyperpolarized 13C Pyruvate as a Biomarker of Aggressiveness & Response to Therapy in Patients With Advanced Solid Tumors

Using metabolic MR imaging in participants with advanced solid tumors, you can determine the signal-to-noise ratio in detecting intra-tumoral hyperpolarized 13C pyruvate/lactate signal in detecting intra-tumoral hyperpolarized 13C pyruvate/lactate signal using metabolic MR imaging. Since the beginning of SOC therapy, the association between clinical outcomes and the percent change from baseline in peak intra-tumoral hyperpolarized lactate-to-pyruvate ratio and kPL has been studied. OUTLINE: Participants will be enrolled in Part A, which is the feasibility, run-in study that includes the iterative modification of coil geometry to optimize imaging parameters within the target tumor lesion. If the results from Part A support further investigation, more participants will be enrolled in Part B, which is a biomarker registry that includes participants who are planning on being treated with either standard-of-care or investigational therapies, and will be followed until discontinuation of the therapy regimen outside of this protocol.

Source link: https://clinicaltrials.gov/ct2/show/NCT05599048

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions